Zentalis Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ZNTL and other ETFs, options, and stocks.About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations.
CEOJulia Marie Eastland
CEOJulia Marie Eastland
Employees166
Employees166
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2014
Founded2014
Employees166
Employees166
ZNTL Key Statistics
Market cap102.23M
Market cap102.23M
Price-Earnings ratio-0.68
Price-Earnings ratio-0.68
Dividend yield—
Dividend yield—
Average volume1.02M
Average volume1.02M
High today$1.42
High today$1.42
Low today$1.33
Low today$1.33
Open price$1.34
Open price$1.34
Volume4.61M
Volume4.61M
52 Week high$3.33
52 Week high$3.33
52 Week low$1.01
52 Week low$1.01
Stock Snapshot
The current Zentalis Pharmaceuticals(ZNTL) stock price is $1.42, with a market capitalization of 102.23M. The stock trades at a price-to-earnings (P/E) ratio of -0.68.
During the trading session on 2025-12-18, Zentalis Pharmaceuticals(ZNTL) shares reached a daily high of $1.42 and a low of $1.33. At a current price of $1.42, the stock is +6.8% higher than the low and still 0.0% under the high.
Trading activity shows a volume of 4.61M, compared to an average daily volume of 1.02M.
The stock's 52-week range extends from a low of $1.01 to a high of $3.33.
The stock's 52-week range extends from a low of $1.01 to a high of $3.33.
Analyst ratings
50%
of 8 ratingsBuy
50%
Hold
50%
Sell
0%
People also own
Based on the portfolios of people who own ZNTL. This list is generated using Robinhood data, and it’s not a recommendation.